Nearly four decades after the discovery of Ebola virus, we still lack licensed vaccines and antiviral therapeutics to treat Ebola virusinfected patients. However, considerable progress has been made in more recent years, and the current outbreak has fuelled major efforts to evaluate candidate therapeutics in clinical trials.
Supportive care that includes largely oral rehydration with solutions containing electrolytes is the typical course of treatment for Ebolainfected patients. Currently, several experimental Ebola virus vaccines confer varying degrees of protective efficacy in animal models. An ideal Ebola virus vaccine would elicit strong and protective responses after a single immunization and have therapeutic benefits. One of the most extensively tested Ebola virus vaccine platforms is based on a replication-competent vesicular stomatitis virus (VSV) expressing Ebola virus glycoprotein(s) (the major viral immunogen). A single dose of 10 7 recombinant VSV particles has been shown to be effective against Ebola, and its close relative Marburg virus, in prophylactic and post-exposure situations in nonhuman primate models (review; Marzi et al., 2011) . The use of replication-competent vaccine viruses always raises safety concerns; however, such concerns will be addressed in current and future clinical trials. Another vaccine platform is based on a replication-defective, chimpanzee adenovirus vector, ChAd3. One study showed that the vaccination of nonhuman primates with a single dose of 10 10 recombinant adenovirus particles expressing the glycoproteins of Z. ebolavirus conferred complete protection from a lethal challenge with Z. ebolavirus, whereas a lower vaccine dosage protected most infected animals (Stanely et al., 2014) . Given the success of this vaccine platform in nonhuman primates, ChAd3 has now entered a Phase I clinical trial to test its safety, tolerability, and immunogenicity in human volunteers. In addition to these and other experimental vaccine platforms, monoclonal antibody therapy has been developed for therapeutic use. In particular, a cocktail of three monoclonal antibodies against the Z. ebolavirus glycoprotein, called ZMapp (developed by Mapp Biopharmaceutical Inc.), provided complete protection in infected nonhuman primates that were already showing signs of Ebola virus disease (i.e., at five days post-challenge) (Qiu et al., 2014) . This success in nonhuman primates prompted the US Food and Drug Administration to approve ZMapp for compassionate use in patients infected with Ebola virus during the current outbreak. Although five patients treated with ZMapp survived their Ebola virus infection, at least two individuals have died from the infection despite receiving the antibody cocktail. Hence, the effectiveness of ZMapp against Ebola virus infection in humans is uncertain and further testing is needed. The antibodies contained in the ZMapp cocktail are produced in tobacco plants, and current stocks of ZMapp have been exhausted.
The development of antiviral drugs against Ebola virus has also progressed. The nucleoside analogs BCX4430 and T-705 (favipiravir) inhibit viral RNA synthesis with a minimal effect on cellular RNA synthesis (Warren et al., 2014; Oestereich et al., 2014) . Studies have demonstrated the efficacy of T-705 against Ebola virus in a rodent model , and of BXC4430 against Marburg virus in a nonhuman primate model (Warren et al., 2014) . Moreover, both compounds also inhibit other medically important, human RNA viruses (Warren et al., 2014; Oestereich et al., 2014) . In particular, T-705 is approved in Japan to combat pandemic influenza. In addition, small molecule therapeutics that include lipid nanoparticle/small interfering RNA technology have been successful in treatment against Ebola virus in nonhuman primates (Geisbert et al., 2010) and have entered clinical trials. Hence, these compounds hold promise as candidates to treat or prevent Ebola infection.
Since the first Ebola outbreak, we have furthered our understanding of this virus and its life cycle, and advances have been made in the development of potential prophylactic and therapeutic treatments. However, we are not there yet, and more basic and translational research is needed. But limited funding has slowed the progress. Additional funding for basic research is essential to identify the virus reservoir, determine the pathogenesis, and identify viral and host targets for antiviral drug discovery. Similarly, more funding for translational research is needed to test novel vaccines and antiviral drugs in nonhuman primates (the gold-standard animal model in Ebola virus research) and to test promising candidates in clinical trials.
The current outbreak is a glaring wake-up call of the devastation the Ebola virus can inflict on the human population. This outbreak has exposed the world's lack of preparedness to respond to and control such infectious disease outbreaks. Our society has concerned itself with the potential of biological terrorist attacks or laboratory-acquired outbreaks; while such scenarios cannot be dismissed, this Ebola virus outbreak makes plain that the true threat of infectious diseases comes from nature. Funding and research (including gain-of-function experiments) must be stable and steady, not dictated by the world's attention, to ensure that we are ready for the next crisis.
